open access

Vol 52, No 2 (2018)
Review Article
Submitted: 2018-01-30
Published online: 2018-02-19
Get Citation

Progress in the treatment of Friedreich ataxia

Geneieve Tai1, Louise A. Corben123, Eppie M. Yiu134, Sarah C. Milne12, Martin B. Delatycki1235
DOI: 10.1016/j.pjnns.2018.02.003
·
Neurol Neurochir Pol 2018;52(2):129-139.
Affiliations
  1. Bruce Lefroy Centre for Genetic Health Research, Murdoch Children's Research Institute, Parkville, Australia
  2. School of Psychological Science, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia
  3. Department of Paediatrics, University of Melbourne, Parkville, Australia
  4. Department of Neurology, Royal Children's Hospital, Parkville, Australia
  5. Victorian Clinical Genetics Services, Parkville, Australia

open access

Vol 52, No 2 (2018)
Review articles
Submitted: 2018-01-30
Published online: 2018-02-19

Abstract

Friedreich ataxia (FRDA) is a progressive neurological disorder affecting approximately 1 in 29,000 individuals of European descent. At present, there is no approved pharmacological treatment for this condition however research into treatment of FRDA has advanced considerably over the last two decades since the genetic cause was identified. Current proposed treatment strategies include decreasing oxidative stress, increasing cellular frataxin, improving mitochondrial function as well as modulating frataxin controlled metabolic pathways. Genetic and cell based therapies also hold great promise. Finally, physical therapies are being explored as a means of maximising function in those affected by FRDA.

Abstract

Friedreich ataxia (FRDA) is a progressive neurological disorder affecting approximately 1 in 29,000 individuals of European descent. At present, there is no approved pharmacological treatment for this condition however research into treatment of FRDA has advanced considerably over the last two decades since the genetic cause was identified. Current proposed treatment strategies include decreasing oxidative stress, increasing cellular frataxin, improving mitochondrial function as well as modulating frataxin controlled metabolic pathways. Genetic and cell based therapies also hold great promise. Finally, physical therapies are being explored as a means of maximising function in those affected by FRDA.

Get Citation

Keywords

Friedreich ataxia, Therapy, Rehabilitation, Gene therapy

About this article
Title

Progress in the treatment of Friedreich ataxia

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 52, No 2 (2018)

Article type

Review Article

Pages

129-139

Published online

2018-02-19

Page views

1698

Article views/downloads

1995

DOI

10.1016/j.pjnns.2018.02.003

Bibliographic record

Neurol Neurochir Pol 2018;52(2):129-139.

Keywords

Friedreich ataxia
Therapy
Rehabilitation
Gene therapy

Authors

Geneieve Tai
Louise A. Corben
Eppie M. Yiu
Sarah C. Milne
Martin B. Delatycki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl